Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2023-07-11 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 持股5%以上股东减持计划时间届满暨减持结果公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from 百奥泰生物制药股份有限公司 regarding the completion of a shareholding reduction plan by shareholders holding more than 5% of the company's shares. It details the shareholders involved, the number of shares held before and after the reduction, the reduction plan timeline, and the results of the reduction. The document is relatively short (2940 characters) and focuses on the results of a shareholding reduction plan, which is a notification about changes in significant share ownership levels. This fits the definition of a Major Shareholding Notification (MRQ). It is not an annual report, earnings release, or any other financial report type, nor is it a regulatory filing or announcement of a report publication. Therefore, the correct classification is MRQ with high confidence.
2023-07-11 Chinese
百奥泰关于本次募集资金投向属于科技创新领域的说明（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation from Bio-Thera Solutions, Ltd. regarding the allocation of funds raised from a specific issuance of A shares in 2023. It extensively discusses the company's business, the use of proceeds for new drug R&D projects, expansion of production facilities, and working capital. It references regulatory frameworks related to securities issuance and innovation policies, and it is dated June 2023. The document is not a financial report itself but a formal statement explaining the use of raised capital and confirming that the funds are directed towards technology innovation projects. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is substantial and contains no financial statements or earnings data, so it is not an Annual Report or Interim Report. It is not a report publication announcement since it contains substantive content rather than just a notice. Therefore, the best classification is CAP with high confidence.
2023-06-26 Chinese
百奥泰2023年度向特定对象发行A股股票发行方案论证分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度向特定对象发行A股股票发行方案论证分析报告（修订稿）" which translates to "2023 Annual Report on the Issuance Plan of A Shares to Specific Objects (Revised)". It is a detailed analysis report concerning a specific issuance of A shares to certain investors. The content includes background, necessity, pricing, feasibility, fairness, impact on shareholders, and commitments related to this specific capital raising activity. It discusses the issuance of shares, pricing methods, regulatory compliance, and the use of proceeds. There is no indication that this is a general annual report, earnings release, or management discussion. Instead, it is a detailed report analyzing and justifying a capital raising transaction through a specific share issuance. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is substantial (13,840 characters), indicating it is the report itself, not just an announcement. Therefore, the correct classification is CAP with high confidence.
2023-06-26 Chinese
百奥泰 第二届董事会第九次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the company's board meeting regarding a specific capital raising activity: the issuance of A shares to specific investors. It includes specifics on the issuance type, pricing, quantity, use of proceeds, and regulatory compliance. The document is not a full financial report but rather a formal announcement of a capital financing plan approved by the board. It references regulatory approvals and includes voting results on the issuance plan. This fits the definition of a Capital/Financing Update (CAP) filing, as it provides updates on company fundraising and capital structure changes. The document length and detail confirm it is not a brief announcement or a simple notice but a substantive update on financing activities.
2023-06-26 Chinese
百奥泰 第二届监事会第八次会议决议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the Supervisory Board meeting of 百奥泰生物制药股份有限公司 on June 26, 2023. The resolutions pertain to the company's plan for a specific issuance of A shares to certain investors, including details on the issuance type, pricing, quantity, use of proceeds, and compliance with regulatory requirements. The document includes voting results and references to filings on the Shanghai Stock Exchange website. The content is focused on the approval and discussion of a capital raising plan through a share issuance to specific investors, which is a financing activity. It is not a full financial report, audit report, or earnings release, nor is it a regulatory filing or announcement of a report publication. The document is substantive and detailed, not a brief announcement or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-06-26 Chinese
百奥泰 关于向特定对象发行A股股票摊薄即期回报与公司采取填补措施及相关主体承诺（修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 百奥泰生物制药股份有限公司 regarding a specific issuance of A shares to certain investors. It includes detailed financial impact analysis on earnings per share, assumptions for the issuance, risk warnings about dilution of immediate returns, and descriptions of the use of proceeds. It also contains commitments from the company's board, senior management, controlling shareholders, and actual controllers regarding measures to mitigate dilution effects and protect shareholder interests. The document references regulatory guidelines and compliance with securities laws. The content focuses on capital raising activities, the impact on shareholders, and related commitments, which aligns with a Capital/Financing Update. It is not a full annual or interim report, nor an earnings release or proxy statement. It is a substantive announcement about a financing event and related measures, not merely a publication announcement or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-06-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.